Literature DB >> 11836440

Haemophilia A and haemophilia B: molecular insights.

D J Bowen1.   

Abstract

This review focuses on selected areas that should interest both the scientist and the clinician alike: polymorphisms within the factor VIII and factor IX genes, their linkage, and their ethnic variation; a general assessment of mutations within both genes and a detailed inspection of the molecular pathology of certain mutations to illustrate the diverse cause-effect relations that exist; a summary of current knowledge on molecular aspects of inhibitor production; and an introduction to the new areas of factor VIII and factor IX catabolism. An appendix defining various terms encountered in the molecular genetics of the haemophilias is included, together with an appendix providing accession numbers and locus identification links for accessing gene and sequence information in the international nucleic acid databases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11836440      PMCID: PMC1187139          DOI: 10.1136/mp.55.1.1

Source DB:  PubMed          Journal:  Mol Pathol        ISSN: 1366-8714


  157 in total

1.  Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation.

Authors:  B Osterud; S I Rapaport
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

2.  The activation of Factor IX by tissue factor-Factor VII in a bovine plasma system lacking Factor X.

Authors:  J Jesty; S A Morrison
Journal:  Thromb Res       Date:  1983-10-15       Impact factor: 3.944

3.  Hemophilia B Leyden: a sex-linked hereditary disorder that improves after puberty.

Authors:  E Briët; R M Bertina; N H van Tilburg; J J Veltkamp
Journal:  N Engl J Med       Date:  1982-04-01       Impact factor: 91.245

4.  Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease.

Authors:  H J Weiss; I I Sussman; L W Hoyer
Journal:  J Clin Invest       Date:  1977-08       Impact factor: 14.808

5.  Activation of human factor IX (Christmas factor).

Authors:  R G Di Scipio; K Kurachi; E W Davie
Journal:  J Clin Invest       Date:  1978-06       Impact factor: 14.808

6.  Characterisation and use of an intragenic polymorphic marker for detection of carriers of haemophilia B (factor IX deficiency).

Authors:  F Giannelli; D S Anson; K H Choo; D J Rees; P R Winship; N Ferrari; C R Rizza; G G Brownlee
Journal:  Lancet       Date:  1984-02-04       Impact factor: 79.321

7.  Changes in phylloquinone epoxidase activity related to prothrombin synthesis and microsomal clotting activity in the rat.

Authors:  A K Willingham; J T Matschiner
Journal:  Biochem J       Date:  1974-06       Impact factor: 3.857

8.  Identification of the molecular defect in factor IX Chapel Hill: substitution of histidine for arginine at position 145.

Authors:  C M Noyes; M J Griffith; H R Roberts; R L Lundblad
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

9.  Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease.

Authors:  E G Tuddenham; R S Lane; F Rotblat; A J Johnson; T J Snape; S Middleton; P B Kernoff
Journal:  Br J Haematol       Date:  1982-10       Impact factor: 6.998

10.  Mutagenic deamination of cytosine residues in DNA.

Authors:  B K Duncan; J H Miller
Journal:  Nature       Date:  1980-10-09       Impact factor: 49.962

View more
  8 in total

1.  Mutation analysis of a cohort of US patients with hemophilia B.

Authors:  Tengguo Li; Connie H Miller; Jennifer Driggers; Amanda B Payne; Dorothy Ellingsen; W Craig Hooper
Journal:  Am J Hematol       Date:  2014-03-03       Impact factor: 10.047

2.  Hemophilia A in a Senior Patient: A Case Report of Spinal Epidural Hematoma as First Presentation.

Authors:  Dong Ki Ahn; Woo Shik Jung; Jae Il Lee
Journal:  Asian Spine J       Date:  2015-06-08

3.  A Novel Missense Mutation, E1623G, in the Human Factor VIII Gene Associated With Moderate Haemophilia A.

Authors:  Habib Onsori; Mohammad Ali Hosseinpour Feizi; Abbas Ali Hosseinpour Feizi
Journal:  Iran Red Crescent Med J       Date:  2014-01-05       Impact factor: 0.611

4.  The CDC Hemophilia B mutation project mutation list: a new online resource.

Authors:  Tengguo Li; Connie H Miller; Amanda B Payne; W Craig Hooper
Journal:  Mol Genet Genomic Med       Date:  2013-08-19       Impact factor: 2.183

5.  Screening of Intron 1 Inversion of the Factor VIII Gene in 130 Patients with Severe Hemophilia A from a Pakistani Cohort.

Authors:  Azhar Sattar; Shabbir Hussain; Muhammad Ikram Ullah; Saqib Mahmood; Shahida Mohsin
Journal:  Turk J Haematol       Date:  2017-03-15       Impact factor: 1.831

6.  Application of Indirect Linkage Analysis for Carrier Detection of Hemophilia A in Kurdistan Region of Iraq: Usefulness of Intron 18 BclI T>A, Intron 19 HindIII C>T, and IVS7 nt27 G>A Markers.

Authors:  Aveen M Raouf Abdulqader; Shwan Rachid; Ali Ibrahim Mohammed; Sarwar Noori Mahmood
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

7.  Liver gene therapy with intein-mediated F8 trans-splicing corrects mouse haemophilia A.

Authors:  Federica Esposito; Hristiana Lyubenova; Patrizia Tornabene; Stefano Auricchio; Antonella Iuliano; Edoardo Nusco; Simone Merlin; Cristina Olgasi; Giorgia Manni; Marco Gargaro; Francesca Fallarino; Antonia Follenzi; Alberto Auricchio
Journal:  EMBO Mol Med       Date:  2022-05-02       Impact factor: 14.260

8.  Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patients.

Authors:  Tim Preijers; Ri Liesner; Hendrika C A M Hazendonk; Pratima Chowdary; Mariëtte H E Driessens; Dan P Hart; Britta A P Laros-van Gorkom; Felix J M van der Meer; Karina Meijer; Karin Fijnvandraat; Frank W G Leebeek; Ron A A Mathôt; Marjon H Cnossen
Journal:  Br J Clin Pharmacol       Date:  2021-05-04       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.